Patents Assigned to GeneSense Technologies, Inc.
  • Small Interfering Rna Molecules Against Ribonucleotide Reductase and Uses Thereof
    Publication number: 20080255065
    Abstract: Small interfering RNA (siRNA) molecules that target a mammalian ribonucleotide reductase gene, and which are capable of inhibiting the expression of their target gene are provided. The siRNA molecules of the invention are capable of attenuating neoplastic cell growth and/or proliferation in vitro and in vivo and, therefore, can be used to attenuate the growth and/or metastasis of various types of mammalian cancers.
    Type: Application
    Filed: August 18, 2005
    Publication date: October 16, 2008
    Applicant: GENESENSE TECHNOLOGIES, INC.
    Inventors: Aiping H. Young, Jim A. Wright
  • Neuropilin antisense oligonucleotide sequences and methods of using same to modulate cell growth
    Patent number: 7087580
    Abstract: This invention relates to oligonucleotides complementary to the neuropilin genes which modulate tumor cell growth and angiogenesis in mammals. This invention is also related to methods of using such compounds in inhibiting the growth of tumor cells and angiogenesis in mammals. This invention also relates to pharmaceutical compositions comprising a pharmaceutically acceptable excipient and an effective amount of a compound of this invention.
    Type: Grant
    Filed: April 22, 1999
    Date of Patent: August 8, 2006
    Assignee: GeneSense Technologies, Inc.
    Inventors: Jim A. Wright, Aiping H. Young, Yoon S. Lee
  • Antisense oligonucleotide sequences as inhibitors of microorganisms
    Patent number: 6610539
    Abstract: This invention relates to antisense oligonucleotides which modulate the expression of the ribonucleotide reductase or the secA genes in microorganisms. This invention is also related to methods of using such oligonucleotides in inhibiting the growth of microorganisms. These antisense oligonucleotides are particularly useful in treating pathological conditions in mammals which are mediated by the growth of microorganisms.
    Type: Grant
    Filed: July 9, 1998
    Date of Patent: August 26, 2003
    Assignee: GeneSense Technologies, Inc.
    Inventors: Jim A. Wright, Aiping H. Young, Dominique Dugourd
  • Suppression of malignancy utilizing ribonucleotide reductase R1
    Patent number: 6472376
    Abstract: The present invention provides a method of modulating the malignant properties of a cell in a human or other mammal by contacting a neoplastic cell with a growth modulating amount of an expressible nucleic acid sequence for ribonucleotide reductase R1 of the mammal. The present invention also provides and uses a growth modulating amount of the ribonucleotide reductase R1 protein or biologically active peptide to modulate the malignant properties of a cell in a human or other mammal. The method provides for a generally elevated expression of the R1 component of mammalian ribonucleotide reductase. The expressible nucleic acid sequence can be in the form of a vector for gene therapy.
    Type: Grant
    Filed: September 24, 1998
    Date of Patent: October 29, 2002
    Assignee: Genesense Technologies, Inc.
    Inventors: Jim A. Wright, Aiping H. Young
  • Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
    Patent number: 6121000
    Abstract: Compounds and methods for modulating cell proliferation, preferably inhibiting the proliferation of tumor cells are described. Compounds that may be used to modulate cell proliferation include antisense oligonucleotides complementary to regions of the mammalian ribonucleotide reductase genes.
    Type: Grant
    Filed: February 11, 1999
    Date of Patent: September 19, 2000
    Assignee: Genesense Technologies, Inc.
    Inventors: Jim A. Wright, Aiping H. Young